AZN Stock Analysis: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$157.97
-11.67 (-6.88%)
▼
5d:
-6.88%
30d:
-19.05%
90d:
-14.49%
HOLD
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Jul 27, 2026
0d
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AZN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AZN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$452.28
Based on 9.4% avg growth
INTRINSIC VALUE TODAY
$280.83
43.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $157.97, which is considered oversold relative to its 30-day fair value range of $165.69 to $186.34. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.6) compared to its historical average (26.0). Remarkably, the market is currently pricing in an annual earnings decline of 19.3% over the next few years. This pessimistic expectation contrasts with the company's recent 2.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, AZN is in a downtrend. The price is currently testing key support at $153.41. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: AZN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $213.69 (+35.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AZN is in a downtrend. The price is currently testing key support at $153.41. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: AZN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $213.69 (+35.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$165.69 -
$186.34
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 35.3% below Wall St target ($213.69)
- CAUTION: 5-day price weakness (-6.9%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$165.69 -
$186.34
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$153.41
Resistance Level
$175.04
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.64
Wall Street Target
$213.69
(+35.3%)
Revenue Growth (YoY)
6.4%
Earnings Growth (YoY)
2.5%
Profit Margin
17.0%
Valuation Discount vs History
-19.3% cheaper
PE vs Historical
13.6 vs 26.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-19.3%
(market-implied from PE analysis)
1-Year Target
$142.17
(-10%)
2-Year Target
$127.96
(-19%)
3-Year Target
$115.16
(-27%)
3-Yr Target (if PE normalizes)
(PE: 14→26)
$219.49
(+39%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 14.8%)
$363.42
(+130%)
Base:
(SPY PE: 13.6, Growth: 14.8%)
$239.15
(+51%)
Bear:
(PE: 11.6, Growth: 14.8%)
$203.28
(+29%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 25.40 | Current EPS (TTM): $6.68
Bull Case
$323.48
(+105%)
Analyst growth 73.4%, PE expands to 27.9
Base Case
$294.08
(+86%)
Market implied 73.4%, PE stable at 25.4
Bear Case
$115.36
(-27%)
Severe decline -20.0%, PE contracts to 21.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.6 to 26.0
Stabilization Target:
$301.08
(+90.6%)
PE Expansion Potential:
+90.6%
Share & Embed Analysis
Last updated: August 04, 2026 8:04 AM ET
Data refreshes hourly during market hours. Next update: 9:04 AM
Data refreshes hourly during market hours. Next update: 9:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1277 | 49 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 56 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$357 | 58 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$270 | 57 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$234 | 56 HOLD |
